Unsatisfied with life?

A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological symptoms

A Maastricht University study found that a single dose of 5-MeO-DMT (the psychedelic found in toad venom and several plants) improved subjects’ scores for life satisfaction, depression, anxiety, and mindfulness. 

The changes were seen 1 day after the dose and persisted for 4 weeks.

Higher levels of ego dissolution were linked with greater improvements in scores (so, the more intense the trip, the more beneficial).

A separate survey found that ~80% of people with depression or anxiety reported improvements in symptoms following a dose of 5-MeO-DMT.

Some companies that are researching 5-MeO-DMT include GH Research (GHRS), Biomind Labs (BMND), and Mindset Pharma (MSET).

PDF of article

PDF of study

Biomind begins DMT trial

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Biomind Labs (BMND) dosed the first subject in a Phase I trial /IIa clinical trial on DMT for treatment-resistant depression.

Over the next 4 months, 30 healthy patients who have never done psychedelics will receive 2 doses of inhalable DMT. Researchers will assess the safety of the drug, as well as behavioral and brain effects before continuing with Phase II.

Can you imagine trying DMT as your first psychedelic?

PDF of article

Magic mushroom dispensaries in Canada’s capital 🍁

This Ottawa store is selling magic mushrooms to protest ‘unjust’ laws

The Golden Teacher is a “grey-area research facility” and mushroom dispensary in Ottawa that wants to make bad trips obsolete.

Owner Jordan Armstrong aims to understand how magic mushrooms affect individuals differently by surveying each customer. The goal is gather data to regulate the fungi properly.

Ottawa’s second mushroom dispensary, Shroomyz, will be opening on May 1st!

Shroomyz is located on Preston Street and The Golden Teacher is on the corner of Rideau and Dalhousie Streets.

Psychedelic startup makes a deal with Big Pharma

Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

Terran Biosciences, a private psychedelic startup, announced a licensing deal with the French Big Pharma company Sanofi (SNY). Terran will license two of Sanofi’s pipeline assets that target central nervous system (CNS) disorders. The assets have generated more than 100 clinical studies involving 15,000 subjects on a variety of CNS disorders.

PDF of article

Attention psychedelic researchers 🚨

Here’s two new opportunities to get your research funded:

  1. COMPASS Pathways (CMPS) is sponsoring three One Mind Rising Star Awards – a $300,000 research grant for mental health researchers.
  2. The Canadian Institutes of Health Research (CIHR) is launching a $3M grant program to support psilocybin clinical trials on:
  • Substance use disorders
  • Major depressive disorder or treatment resistant depression
  • End-of-life distress in late-stage cancer patients

PDF of article 1

PDF of article 2

“I felt joy like I’ve never experienced”

‘I felt more joy than I thought possible’

Steve struggled with depression for 30 years. Traditional antidepressants numbed both his highs and lows, leaving him feeling like a “functional zombie”.

Things finally changed when he volunteered for a psilocybin trial at Imperial College London.  

“With the first dose, I felt joy like I’ve never experienced – and more like myself than I’ve ever felt… It took from not knowing myself at all to having a sense of what my place was in the greater scheme of things,” he said.

The second dose was much more challenging, but “therapeutically more useful,” as it forced him to deal with suppressed emotions.

“The drug gives us part of a healing process. It exposes you to different possibilities – another way of being,” Steve explains.

PDF of article